We are the forerunner and incontrovertible leader of Chinese biopharmaceutical industry
As a leading company in China’s rapidly growing biopharmaceutical industry, we have a wealth of expertise in products under study, listed products that have leading market share, manufacturing and marketing services.
Research and development is our constan original intention
We have successfully achieved good results under the support of a comprehensive R & D platform. 3SBio relies on a professional R & D team composed of more than 300 scientists, and has a national engineering research center of antibody-based drugs and four comprehensive research and development centers of dual platform for biological and chemical drugs. Our comprehensive R & D expertise covers the discovery and development of biological drugs, including molecular cloning, gene expression, cell line construction and process development, as well as preclinical and clinical trials. The design and management of manufacturing process development and analysis process development is used for quality control and guarantee. Our R & D team spare no effort to accelerate the progress of clinical trials and develop breakthrough treatment protocols. We strive to work with global innovation partners to develop new products. Our R & D capabilities also make us one of the few Chinese companies that have signed licenses and licensing agreements with international partners. At present, we have a wealth of product series under study, and 25 kinds of alternative products, of which 16 serves as a new class of Chinese medicine. We have always focused on the development of leading biological drugs, including priming injections such as Trastuzumab, Rituximab, second-generation long-acting recombinant human erythropoietin (NuPIAO) and anti-tumor necrosis factor (anti-TNF), Pesiticase, Cetuximab, Etanercept and other McAb products.
Stick to quality control to create superior products
We have five major production bases in the world, located in: Shenyang, Shanghai, Shenzhen, Hangzhou and Italy. We have accumulated a wealth of professional experience and knowledge in the manufacture of biopharmaceuticals. We are able to effectively and steadily achieve volume production of biological drugs, while ensuring the high quality of drugs. We have advanced production equipment: 11 production lines for antibody drugs, with a production capacity of more than 38,000 liters, and production lines for small molecular products, mammalian cell products and bacterial cell products. 3SBio’s production lines are awarded the latest certification of Good Manufacturing Practice (GMP) by China Food and Drug Administration. 3SBio has implemented an unified quality management standards, and each of the raw materials are referred to the United States Pharmacopoeia, European Pharmacopoeia and Chinese Pharmacopoeia, and the relevant quality standards have been established to allow the raw materials to enter into the production process after rigorous testing. 3SBio’s drug registration standards have consistently adhered to the standards higher than the European Pharmacopoeia and Chinese Pharmacopoeia. 3SBio's antibody drugs are demarcated as national standards which are used for preparing and demarcating monoclonal antibody products by the China Food and Drug Administration (CFDA), and 3SBio has been allowed to participate in the development of 3 items of drug national standards.
Our products cover various therapeutic fields, such as tumor, autoimmunity, nephrology, metabolism and dermatology and are in the market leading position and have strong growth momentum and huge growth potential:
• TPIAO: The world’s only commercial recombinant human thrombopoietin (rhTPO) which is an independent research and development product
• Etanercept: TNF-inhibitor that has the first market share in China
• Epiao and Sepo: The leaders of China’s recombinant human erythropoin market
• Enter into an exclusive license agreement with AstraZeneca, obtaining the commercialization rights for Type 2 diabetes drugs Byetta and Bydureon in China
• Enter into the exclusive license agreement with Lilly China, obtaining the commercialization rights for insulin product Humulin® in China
Compliance academic and promoting the development of medical and health services is the foundation of our undertaking
We have a leading business platform, matched with six major business units (EBU, TBU, GBU, WBU, CBU, MBU), and a professional team of medical information communication composed of about 1929 is committed to the promotion of professional compliance academics.We already have integrated compliance, market access, business operations, marketing, sales team efficiency and financial team, and the overall efficiency continues to improve. After years of professional training, we have established and maintained a solid relationship with leading hospitals and medical specialists; and our academic recognition and brand awareness have been promoted and strengthened within the medical experts.
Benefiting global patients with high quality drugs is our supreme goal
We are continually devote ourself to our global business expansion. So far, Etanercept has obtained the listing approval in 9 countries, and is in a registration stage in 18 countries. We will be conduct a clinical trial for Tpiao in the United States, which is going to be approved in India and Mexico; and we have been conducting a multi-center biomimetic clinical trial for Epiao in Russia and Thailand. In the future, our goal is to achieve registration of new products in highly regulated markets through biosimilars.
Our core values
China Bio-pharmaceutical Brand Enterprise
A leading company in attractive China bio-pharmaceutical industry, with 7 approved biopharmaceuticals
Strong innovation ability
Has special and innovative product lines under investigation, including 16 State first class new medicines
Has products with great growth potential in Oncology, Rheumatology, Nephrology and Metabolism
Advanced production facilities
Covers monoclonal antibodies, mammalian cells, bacteria, and chemically synthesized molecules
Leading commercial channel
More than 1900 medical information liaison officers provide doctors with more timely, scientific, and rigorous academic information
Visionary management team
Experienced and visionary management team leads the company